Sheena Jonathan, who is both a co-founder and a director at Natera, Inc. (NASDAQ: NTRA), completed the sale of 1,500 shares of the company’s common stock on April 17, 2026, bringing in aggregate proceeds of $299,440. The transactions were carried out under previously established Rule 10b5-1 trading plans that Ms. Jonathan adopted on June 7, 2024.
The sales were executed through two indirect holdings - the Caraluna 1 Trust and the Caraluna 2 Trust - each disposing of 750 shares. Across the two transactions, weighted average prices per share fell between $199.5906 and $199.664. The company’s shares are trading at $205.42 at the time of reporting, corresponding to a market capitalization of $29.17 billion.
Details of the two trust-level transactions are as follows:
- Caraluna 1 Trust: Sold 750 shares at a weighted average price of $199.6640 per share. Individual sale prices within this lot ranged from $199.1950 to $199.9750 per share. After the sale, the Caraluna 1 Trust holds 20,282 shares.
- Caraluna 2 Trust: Sold 750 shares at a weighted average price of $199.5906 per share, with individual sales occurring between $199.1950 and $199.9550 per share. Following the transaction, the Caraluna 2 Trust also holds 20,282 shares.
Ms. Jonathan disclaims beneficial ownership of the securities held by both trusts; those shares are held for the benefit of the respective beneficiaries of each trust. In addition to the indirect holdings, Ms. Jonathan directly owns 259,255 shares of Natera common stock following these transactions.
These insider sales come as Natera’s shares have appreciated roughly 42% over the past year. Despite the share-price appreciation, the company remains unprofitable and analysts are not forecasting profitability this year. An independent analysis suggests the stock may be priced above its Fair Value.
Alongside the insider activity, Natera has reported several corporate developments. A United States District Court in Delaware issued a decision that grants Natera a 30% ongoing royalty on certain product sales by Invitae. Separately, the company added Eric Rubin to its board of directors; the appointment increases the board’s membership to eleven and was recommended by Natera’s Nominating, Corporate Governance and Compliance Committee.
On the product front, Natera launched Zenith genomics, a whole genome sequencing assay intended to expand rare genetic condition detection capabilities. The company’s Signatera circulating tumor DNA (ctDNA) assay has also shown encouraging results in recent studies focused on anal and rectal cancers, with findings that indicate potential benefits for patient survival.
Finally, William Blair has opened coverage of Natera with an Outperform rating, reflecting that firm’s view of the company’s competitive positioning in diagnostics markets.
The transactions by Ms. Jonathan were carried out under scheduled trading arrangements permitted by Rule 10b5-1, which allow insiders to set predetermined plans for buying or selling shares at future dates. No further material details regarding changes to those plans were disclosed in the filings that reported the April 17, 2026 sales.
Investors seeking more detailed company research and financial modeling on Natera have access to comprehensive reports covering this company and a broad set of U.S. equities.